Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc.

Overview
Date Founded

1985

Headquarters

3661 Horseblock Road, Medford, NY, 11763, USA

Type of Company

Public

Employees (Worldwide)

295

Industries

Pharmaceuticals
Hospitals & Patient Services

Company Description

Chembio Diagnostics, Inc. develops, manufactures, markets and licenses rapid point-of-care diagnostic tests that detect infectious diseases. Its products include human and veterinary diagnostics. The company was founded in 1985 and is headquartered in Medford, NY.

Contact Data
Trying to get in touch with decision makers at Chembio Diagnostics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & President

Executive Vice President & Chief Financial Officer

Senior Vice President, Chief Operations Officer

Senior Vice President & Chief Commercial Officer

Executive Vice President, Chief Science & Technology Officer

Vice President, Quality & Regulatory Affairs

Vice President, Research & Development

Data Processing Executive

Regional Director, Latin America

Regional Director, Asia Pacific

Board of Directors

Managing Director at Golden Seeds LLC

Executive Chairman at Sword Diagnostics, Inc.

Chief Executive Officer & President at Chembio Diagnostics, Inc.

Chief Executive Officer at Elligo Health Research, Inc.

Paths to Chembio Diagnostics, Inc.
Potential Connections via
Relationship Science
You
Chembio Diagnostics, Inc.
Owners & Shareholders
Details Hidden

ARS Investment Partners' investment approach is centered on the belief that making investment decisions based solely on stock market timing is counterproductive. Rather, the firm's research focuses on addressing the economic, social and political environment which leads them to sectors in the economy that are likely to thrive and to which capital will flow. They then apply evaluation standards to identify companies that stand to benefit the most from the identified trends.In making investment selections, ARS screens a narrow list of companies on three levels: value screens, growth screens and soft screens. Valuation screens include: p/e, price/cash flow, price/sales, market value/asset value and market value/reserve value. The growth screens target the earnings growth rate, cash flow growth rate, free cash flow growth rate and product cycles. The soft screens identify factors such as institutional ownership, relative value to peers, insider ownership, relative value to the S&P 500, analyst coverage, relative historic valuation and dividend yield. The ability of company management to execute is a critical factor in the investment selection process. ARS evaluates companies on an enterprise value basis as if they were purchasing the entire company.ARS offers advice on the following types of securities: equity and fixed income securities including exchange-listed securities, securities traded OTC and ADRs; corporate and municipal debt; CDs, US Government securities; mutual fund and ETF fund shares; warrants and certain rights; and options contracts on securities.

Details Hidden

Millrace Asset Group manages the Millrace Fund, a long/short US small-cap equity portfolio

Details Hidden

Gagnon Advisors LLC, a subsidiary of Gagnon Administrative Services LLC, is a company headquartered in New York, NY. The firm provides investment advice. It was founded in 2001. Neil Joseph Gagnon is the current CEO of the firm.

Recent Transactions
Details Hidden

Chembio Diagnostics, Inc. purchases optricon Entwicklungs GmbH für Optische Technologien from IBB Beteiligungsgesellschaft, Ventegis Capital AG (Venture Capital)

Details Hidden

Chembio Diagnostics, Inc. issued USD Common Stock

Details Hidden

Chembio Diagnostics, Inc. issued USD Common Stock

Transaction Advisors
Auditor

Advised onChembio Diagnostics, Inc. issued USD Common Stock

Underwriter

Advised onChembio Diagnostics, Inc. issued USD Common Stock

Escrow Agent

Advised onChembio Diagnostics, Inc. issued USD Common Stock

Public Relations

Advised onChembio Diagnostics, Inc. issued Common Stock

Founder

Advised onChembio Diagnostics, Inc. issued Common Stock

Founder & Chairman

Advised onChembio Diagnostics, Inc. issued USD Common Stock

Advisors & Consultants
Publicist

Founder at Gilmartin Group LLC

Consultant

Former Chief Executive Officer at Chembio Diagnostics, Inc.

Publicist

President & Chief Executive Officer at Vida Strategic Partners, Inc.

Clients

The Bill & Melinda Gates Foundation was formed in 1997 as the William H. Gates Foundation. In 1999, the foundation was renamed the Bill & Melinda Gates Foundation. The Bill & Melinda Gates Foundation Trust was created in January 2000 through the merger of the Gates Learning Foundation, which worked to expand access to technology through public libraries and the William H. Gates Foundation, which focused on improving global health. The foundation participates in preventive approaches and collaborative endeavors with government, philanthropic and not-for-profit partners. Priority is given to grants that leverage additional support and serve as a catalyst for long-term, systemic change. The foundation also provides funds to promote greater equity in global health, education and public libraries. Through their partnerships in communities across the US, the Bill & Melinda Gates Foundation is committed to raising the high school graduation rate and helping all students, regardless of race or family income. The foundation is headquartered in Seattle, Washington.

AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 6012, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

The Paul G. Allen Family Foundation, founded in 1988 by Paul Allen and his sister Jody Allen, has invested nearly half of a billion dollars into improving communities throughout the Pacific Northwest and beyond. Our purpose is to light up the world with meaningful change, starting close to home and moving around the globe. We want our work to fund field-changing research. To give first-time entrepreneurs the tools to rewrite their futures. To enable artists to make sense of the complexities of our world.

Key Stats and Financials As of 2018
Market Capitalization
$132M
Total Enterprise Value
$69.5M
Earnings Per Share
$-0.55
Revenue
$33.4M
Net Profit
$-7.87M
Debt TEV
0.01x
TEVNet Income
-8.84x
Enterprise Value Sales
2.08x
Total Debt
$380K
Total Equity
$33.3M
Three Year Compounded Annual Growth Rate Of Revenue
11.26%
Five Year Compounded Annual Growth Rate Of Revenue
2.49%
EBITDAMargin
-20.28%
EBITDA
$-6.78M
Non-Profit Donations & Grants Received
Suppliers
Bio-Rad Laboratories Inc. Industrial Machinery & Manufacturing | HERCULES, CA

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the following segments: Life Sciences and Clinical Diagnostics. The Life Science segment develops, manufactures and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialize in quality controls that serve clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Competitors
Abbott Laboratories Pharmaceuticals - Abbott Park, Illinois

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

OraSure Technologies, Inc. Medical Products & Equipment - Bethlehem, PA

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices. The DNAG segment manufactures and sells specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.

Trinity Biotech Plc Pharmaceuticals - Bray, WW

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Chembio Diagnostics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Chembio Diagnostics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Chembio Diagnostics, Inc..